Juniper Pharmaceuticals Soars on Catalent Buy Out

Shares of Juniper Pharmaceuticals, a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health, saw its shares rise after the company announced a definitive agreement with Catalent, Inc.

The stock jumped a little over 31% after Juniper said that Catalent will acquire all of the outstanding shares of the comapny at a price of $11.50 per share in cash.

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company will support Juniper’s Crinone franchise, a progesterone gel that is the single largest revenue source, marketed by Merck KGaA MKGAF outside of the United States.

The closing of the transaction is expected to take place in the third quarter.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” said Jonathan Arnold, president of Catalent Oral Drug Delivery.

Disclaimer: We have no position in Juniper Pharmaceuticals Inc. (NASDAQ: JNP) nor Catalent Inc. (NYSE: CTLT) and have not been compensated for this article.